The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PCVX | -62.4% | -3.03% | -0.61% | +61% |
| S&P | +16.9% | +95.99% | +14.39% | +123% |
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$4.99M | -43.4% |
| Market Cap | $4.19B | -48.9% |
| Market Cap / Employee | $10.13M | 0.0% |
| Employees | 414 | 63.0% |
| Net Income | -$166.57M | -29.4% |
| EBITDA | -$221.23M | -48.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $306.74M | -40.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $79.54M | 334.9% |
| Short Term Debt | $6.30M | -13.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -20.31% | 7.4% |
| Return On Invested Capital | -25.69% | 15.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$130.92M | 21.5% |
| Operating Free Cash Flow | -$121.17M | 0.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 6.36 | 2.98 | 1.43 | 1.31 | -68.35% |
| Price to Tangible Book Value | 6.36 | 2.98 | 1.43 | 1.31 | -68.35% |
| Enterprise Value to EBITDA | -88.48 | -54.31 | -20.12 | -12.87 | -74.10% |
| Return on Equity | -21.1% | -20.4% | -19.7% | -21.7% | -25.55% |
| Total Debt | $27.96M | $71.11M | $87.21M | $85.85M | 235.58% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
